Life Science Investing Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
Life Science Investing Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Life Science Investing Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg in Waldenström Macroglobulinemia at the 67th American Society of Hematology Annual Meeting and Exposition
Life Science Investing Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting & Exposition
Life Science Investing Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg To Be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
Life Science Investing Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Life Science Investing Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
Life Science Investing Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
Life Science Investing Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology Annual Meeting
Life Science Investing Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
Life Science Investing Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
Life Science Investing Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
Life Science Investing Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology Congress
Life Science Investing Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Life Science Investing Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Kobo Resources Advances Kossou Toward Resource Definition While Expanding Gold Mineralisation Beyond Known Structures
Nextech3D.ai's KraftyLab Accelerates Global Scale with Launch of In-Person Experiences and AI-Driven Platform Automation
CHARBONE obtient une premiere commande d'hydrogene propre UHP d'un client americain dans l'Etat de NY
Skyharbour Intersects High-Grade Uranium in Drill Hole ML25-15 at the Maverick Main Zone Returning 11.77% U3O8 over 1.6 metres within 4.4 metres of 4.84% U3O8 and Identifies a New Prospective Regional Target Area called Nomad at the Moore Project
